Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing medicines to improve survival and quality of life of cancer patients. Our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Our people are inspired by the strength, tenacity and courage of those battling cancer. Verastem team is anchored by core values of character, urgency, respect, and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence.
We believe that empowering employees is what makes them truly care about the important work they do. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
Our people are inspired by the strength, tenacity and courage of those battling cancer. Verastem team is anchored by core values of character, urgency, respect, and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence.
We believe that empowering employees is what makes them truly care about the important work they do. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
Location: United States, Massachusetts, Needham
Employees: 51-200
Total raised: $48M
Founded date: 2010
Investors 6
| Date | Name | Website |
| 24.11.2025 | Foresite C... | foresiteca... |
| - | Hercules C... | htgc.com |
| - | Bessemer V... | bvp.com |
| 30.08.2023 | OrbiMed | orbimed.co... |
| - | Lightstone... | lightstone... |
| - | Cardinal P... | cardinalpa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.07.2011 | Series B | $32M | - |
| 16.11.2010 | Series A | $16M | - |
Mentions in press and media 12
| Date | Title | Description |
| 14.01.2025 | Verastem Oncology: $150 Million Credit Facility Deal Signed | Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced a new credit facility for up to $150 million and an equity investment of $7.5 million with Ober... |
| 28.08.2024 | A New Dawn in Lung Cancer Treatment: GenFleet's KRAS G12C Inhibitor Approved in China | In a groundbreaking move for cancer treatment, GenFleet Therapeutics has received approval from China's National Medical Products Administration (NMPA) for its KRAS G12C inhibitor, Dupert® (fulzerasib). This marks a significant milestone in... |
| 23.08.2024 | GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation | SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dup... |
| 19.06.2024 | GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation | SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration (NMPA) has appro... |
| 09.04.2024 | GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting | SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an ora... |
| 24.01.2023 | Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock | - |
| 18.03.2021 | Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022 | BOSTON--(BUSINESS WIRE)--Mar 18, 2021-- Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the... |
| 02.03.2021 | Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference | BOSTON--(BUSINESS WIRE)--Mar 2, 2021-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will part... |
| 12.05.2016 | The man at the center of the secret OxyContin files | A Kentucky judge’s order to unseal secret OxyContin records is putting the spotlight on a wealthy, publicity-averse doctor whose testimony about the marketing of the addictive pain pill is the most prized document in the court files. Dr. Ri... |
| 14.07.2011 | Verastem Raises $32M in Series B Funding | Verastem, Inc., a Cambridge, MA-based biopharmaceutical company focused on discovering and developing drugs to treat cancers by targeting cancer stem cells, has raised $32m in Series B funding. The round was led by Advanced Technology Ventu... |
Show more